Press "Enter" to skip to content


Boise Kidney & Hypertension Institute’s Research Division aims to set the standard in clinical research. With an overriding concern for patient safety, BKHI Research Division provides premier research professionals to conduct all clinical trial related activities with the utmost accuracy and timeliness, while ensuring personable and professional patient care and conduct.

Boise Kidney has been conducting research in the Treasure Valley since opening in 2005. Our team has written and conducted investigator initiated trials to further the areas of chronic kidney disease, anemia management, and dialysis treatment standards of care. Boise Kidney has also participated in many pharmaceutical sponsored clinical research trials for a variety of indications including: Anemia, Catheter Occlusion, Home Hemodialysis, Artery Calcification, Diabetes, and Hypertension.

Under the direction of Arnold Silva, MD, PhD, Boise Kidney & Hypertension Institute partners with Frenova Renal Research to conduct clinical trials. Frenova Renal Research, a Fresenius Medical Care North America company, is the only Phase I-IV drug and device clinical development services provider dedicated exclusively to renal research. Frenova provides access to the largest renal research site network in the world.

Boise Kidney & Hypertension Institute is a member of the Frenova F1RST Up alliance, a highly select group of sites chosen for their expertise in renal research and track record of rapid patient recruitment and retention.

Currently Enrolling Studies:

For more information about each trial, click on the links below.

Click: Trial Information|Identifier: NCT02876835
Sponsor: GlaxoSmithKline – AnemiaMulti-center event driven study in Non-dialysis participants with Anemia associated with Chronic Kidney Disease.
Click: Trial Information|Identifier: NCT03400033
Sponsor: GlaxoSmithKline – AnemiaThis Phase 3 study in hemodialysis-dependent subjects with anemia will evaluate the efficacy and safety of daprodustat administered three-times weekly compared to epoetin alfa, the current standard of care. This study includes a 4-week Screening Period, a 52 week Treatment Period and a 4 to 6 week follow-up period. Each subject will remain in the study for up to 62 weeks. Approximately 402 subjects will be randomized to receive either daprodustat three times weekly or epoetin alfa three-times weekly or once weekly, depending on dose level.
Click: Trial Information|Identifier: NCT02648347
Sponsor: Akebia – AnemiaA multicenter, randomized, open-label, active-controlled Phase 3 study for the correction of anemia and maintenance of hemoglobin (Hb) in subjects with NDD-CKD.
Click: Trial Information|Identifier: NCT03749447
Sponsor: Reata – Eagle – Alport SyndromeThis extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or until patient withdrawal, whichever is sooner.
Click: Trial Information|Identifier: NCT02836574
Sponsor: inRegen – T2DM, Diabetic NephropathyThe purpose of the present study is to compare the safety and efficacy of up to 2 injections of NKA given 3 to 6 months apart (maximum) in subjects who are randomized to receive their first treatment as soon as the NKA product is made available versus subjects who are randomized to undergo contemporaneous, standard-of-care treatment for CKD during the first 12 18 months prior to receiving up to 2 injections of NKA.
Click: Trial Information|Identifier: NCT03824587
Sponsor: Ardelyx – HyperphosphatemiaThis is a randomized, double-blind, placebo-controlled study to evaluate the effect of tenapanor on change in s-P levels when tenapanor is administered orally, twice daily for 28 days as adjunctive therapy to ESRD subjects with hyperphosphatemia on stable phosphate binder therapy.
Click: Trial Information|Identifier: NCT03281538
Sponsor: Cara Therapeutics, Inc. – Uremic PruritusOpen-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.
Click: Trial Information|Identifier: NCT03762850
Sponsor: Retrophin, Inc. – IgA NephropathyTo determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).